Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation
Fiscon G.;
2022-01-01
Abstract
Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in patients with resected stage I to III non-small-cell lung cancer (NSCLC) harbouring an activating EGFR mutation.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
